Ep-CAM expression in pancreatic and ampullary carcinomas: Frequency and prognostic relevance

Journal of Clinical Pathology

Volumn 61, Issue 1, 2008, Pages 31-35

  Fong, Dominic ^a,b   Steurer, M ^a   Obrist, P ^a   Barbieri, V ^a   Margreiter, R ^a   Amberger, A ^a   Laimer, K ^a   Gastl, G ^a   Tzankov, A ^a   Spizzo, G ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b Division of Hematology   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

EPITHELIAL CELL ADHESION MOLECULE; PARAFFIN; CELL ADHESION MOLECULE; TACSTD1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; AMPULLARY CARCINOMA; ARTICLE; BILE DUCT CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER THERAPY; CANCER TISSUE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENE OVEREXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PANCREAS CARCINOMA; PRIORITY JOURNAL; ADENOCARCINOMA; BILE DUCT TUMOR; METABOLISM; MIDDLE AGED; PANCREAS TUMOR; PATHOLOGY; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; VATER PAPILLA;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; AMPULLA OF VATER; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; COMMON BILE DUCT NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 38449097632     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.037333     Document Type: Article

References (25)

1. Warshaw AL, Fernandez-del Castillo C. Pancreatic carcinoma. N Engl J Med 1992;326:455-65.
2. Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas - 616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4:567-79.
3. Litvinov SV, Balzar M, Winter MJ, et al. Epithelial cell adhesion molecule (Ep-CAM) modulates cell-cell interactions mediated by classic cadherins. J Cell Biol 1997;139:1337-48.
4. de Graaf M, Boven E, Oosterhoff D, et al. A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br J Cancer 2002;86:811-8.
5. Martin IG, Cutts SG, Birbeck K, et al. Expression of the 17-1A antigen in gastric and gastro-oesophageal junction adenocarcinomas: a potential immunotherapeutic target? J Clin Pathol 1999;52:701-4.
6. Prang N, Preithner S, Brischwein K, et al. Cellular and complement-dependent cytotoxicity of Ep-CAM-specific monoclonal antibody MT201 against breast cancer cell lines. Br J Cancer 2005;92:342-9.
7. Naundorf S, Preithner S, Mayer P, et al. In vitro and in vivo activity of MT201, a fully human monoclonal antibody for pancarcinoma treatment. Int J Cancer 2002;100:101-10.
8. Heiss MM, Strohlein MA, Jager M, et al. Immunotherapy of malignant ascites with trifunctional antibodies. Int J Cancer 2005;117:435-43.
9. Riethmuller G, Holz E, Schlimok G, et al. Monoclonal antibody therapy for resected Dukes'C colorectal cancer: Seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-94.
10. Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th edn (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
11. th edn. Berlin, Springer-Verlag, 1997.
12. Gastl G, Spizzo G, Obrist P, et al. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 2000;356:1981- 2.
13. Cirulli V, Crisa L, Beattie GM, et al. KSA antigen Ep-CAM mediates cell-cell adhesion of pancreatic epithelial cells: morphoregulatory roles in pancreatic islet development. J Cell Biol 1998;140:1519- 34.
14. Levi E, Klimstra DS, Andea A, et al. MUC1 and MUC2 in pancreatic neoplasia. J Clin Pathol 2004;57:456-62.
15. de Bono JS, Tolcher AW, Forero A, et al. ING-1, a monoclonal antibody targeting Ep-CAM in patients with advanced adenocarcinomas. Clin Cancer Res 2004;10:7555-65.
16. Mosolits S, Markovic K, Frodin JE, et al. Vaccination with Ep-CAM protein or antiidiotype antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients. Clin Cancer Res 2004;10:5391-402.
17. Himmler M, Settaf A, Groiss F, et al. A randomized placebo-controlled phase II study with the cancer vaccine candidate IGN101 in patients with epithelial cancers [abstract]. J Clin Oncol 2005;23(suppl 1):2555.
18. Samonigg H, Himmler M, Gnant M, et al. A multicenter phase II, open-label trial of multiple doses of cancer vaccine candidate IGN101 to evaluate efficacy against disseminated tumor cells in blood [abstract]. J Clin Oncol 2005;23(suppl 1):2557.
19. Piyathilake CJ, Frost AR, Weiss H, et al. The expression of Ep-CAM (17-1A) in squamous cell cancers of the lung. Hum Pathol 2000;31:482-7.
20. Litvinov SV, van Driel W, van Rhijn CM, et al. Expression of Ep-CAM in cervical squamous epithelia correlates with an increased proliferation and the disappearance of markers for terminal differentiation. Am J Pathol 1996;148:865-75.
21. Munz M, Kieu C, Mack B, et al. The carcinoma-associated antigen EpCAM upregulates c-myc and induces cell proliferation. Oncogene 2004;23:5748-58.
22. Osta WA, Chen Y, Mikhitarian K, et al. EpCAM is overexpressed in breast cancer and is a potential target for breast cancer gene therapy. Cancer Res 2004;64:5818-24.
23. Spizzo G, Went P, Dirnhofer S, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 2004;86:207-13.
24. Varga M, Obrist P, Schneeberger S, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res 2004;10:3131-6.
25. Slack JM. Developmental biology of the pancreas. Development 1995;121:1569-80.